CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025
MWN-AI** Summary
On October 21, 2025, CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, will present at the LD Micro "Main Event" Investor Conference. CEO Geert Kersten is set to share insights into the company's strategic roadmap focused on the development of Multikine, an innovative cancer therapy. The presentation is scheduled for 9:30 a.m. PST and will be available to registered viewers via a link provided by the company.
Multikine, derived from Leukocyte Interleukin, is designed to prime the immune system to target tumors before they are subjected to surgery, radiation, or chemotherapy, thereby maximizing therapeutic efficacy. This first-line therapy has been successfully administered to over 740 patients and holds Orphan Drug designation from the FDA for use in neoadjuvant therapy for squamous cell carcinoma of the head and neck. Notably, following a randomized controlled Phase 3 study with 928 participants, the FDA approved CEL-SCI to initiate a confirmatory Registration Study that will enroll an additional 212 patients. This study specifically targets newly diagnosed patients with resectable head and neck cancer who exhibit low PD-L1 tumor expression.
CEL-SCI operates out of Vienna, Virginia, and nearby Baltimore, Maryland, while remaining focused on advancing Multikine through stringent clinical trials. The company’s pursuit of this groundbreaking therapy is underscored by its commitment to enhancing patient survival rates through immunological bolstering.
The press release also mentions that forward-looking statements are included, cautioning that actual results may differ due to various factors, including regulatory approvals and clinical outcomes. CEL-SCI remains dedicated to its mission of improving treatment options for cancer patients while navigating the complexities inherent in drug development.
MWN-AI** Analysis
As CEL-SCI Corporation (NYSE American: CVM) prepares for its presentation at the LD Micro "Main Event" on October 21, 2025, investors should closely analyze the strategic insights shared by CEO Geert Kersten regarding the development of Multikine, its pioneering cancer immunotherapy. The company's innovative approach, focusing on enhancing the immune system's function pre-treatment, positions it uniquely within the oncology landscape.
Investors are encouraged to pay particular attention to the details concerning the ongoing confirmatory Registration Study enrolling 212 patients with locally advanced, resectable head and neck cancer. This study follows a sizable Phase 3 trial with promising results involving over 900 patients. Such backing from the FDA, including Orphan Drug designation, could be pivotal for the company. The estimated annual patient pool of 100,000 reinforces the market potential for Multikine, suggesting that successful results could drive substantial revenue growth and heighten investor interest.
However, potential investors must also regard the inherent risks presented by CEL-SCI's forward-looking statements. There are uncertainties about replication of clinical results, necessary capital requirements, and potential regulatory challenges. As outlined in the company's filings, these risks underscore a cautious approach for anyone considering an investment in CEL-SCI.
Attending the virtual presentation could provide invaluable context surrounding the company’s roadmap, investment strategies, and updates on clinical trials. It may also clarify the management's long-term vision for Multikine, contributing to more informed decision-making.
In conclusion, while CEL-SCI offers an intriguing investment proposition, due diligence is key. Close monitoring of the presentation and subsequent developments will be crucial for those considering exposure to this dynamic segment of the biotech market.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Vienna, Virginia--(Newsfile Corp. - October 20, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, previously announced that Geert Kersten, Chief Executive Officer, is scheduled to present at the LD Micro "Main Event" Investor Conference on October 21, 2025. You can register to watch the virtual presentation at 9:30 a.m. PST by following this link: https://ldmicrocasts.com/#register.
Mr. Kersten will deliver a 20-minute corporate presentation highlighting the Company's strategic roadmap for the continued development of Multikine*.
About CEL-SCI Corporation
CEL-SCI believes that boosting a patient's immune system while it is still intact should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor before surgery, radiation and chemotherapy because that is the time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.
Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. Based on the data from the completed randomized controlled Phase 3 study of 928 patients, the FDA concurred with CEL-SCI's target patient selection criteria and gave the go-ahead to conduct a confirmatory Registration Study which will enroll 212 patients. CEL-SCI will enroll newly diagnosed locally advanced not yet treated resectable head and neck cancer patients with no lymph node involvement (determined via PET scan) and with low PD-L1 tumor expression (determined via biopsy), representing about 100,000 patients annually.
The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2024. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.
COMPANY CONTACT:
Gavin de Windt
CEL-SCI Corporation
(703) 506-9460
###
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270944
FAQ**
What specific advantages does CEL-SCI Corporation CVM see in its Vienna, Virginia operations that support the development of Multikine, particularly in the context of cancer immunotherapy?
How does the presence of CEL-SCI Corporation CVM in Vienna, Virginia, impact its collaborations with local research institutions and healthcare providers in advancing clinical trials?
What role does the local regulatory environment in Virginia play in the progress and strategy of CEL-SCI Corporation CVM as it seeks FDA approvals for its therapies?
Can you elaborate on any community outreach or engagement initiatives by CEL-SCI Corporation CVM in Vienna, Virginia, aimed at raising awareness about cancer treatments and clinical trials?
**MWN-AI FAQ is based on asking OpenAI questions about Cel-Sci Corporation (NYSE: CVM).
NASDAQ: CVM
CVM Trading
0.12% G/L:
$4.075 Last:
11,027 Volume:
$4.06 Open:
